1. travel
2. tourist destinations
3. italy

CONSENSUS CONFERENCE FOR THE
METABOLIC DIAGNOSIS AND MEDICAL
PREVENTION OF CALCIUM
NEPHROLITHIASIS AND ITS SYSTEMIC
MANIFESTATIONS
(& Educational course on renal stone disease)
Rome (Italy), March 26 – 28, 2015
Organized by
DIVISION OF NEPHROLOGY AND DIALYSIS
COLUMBUS-GEMELLI UNIVERSITY HOSPITAL
UNIVERSITÀ CATTOLICA DEL SACRO CUORE, ROME, ITALY
Promoted by
PROGRAM
Palazzo Brancaccio
Viale del Monte Oppio, 7 - Largo Brancaccio, 82/a
CONSENSUS CONFERENCE FOR THE
METABOLIC DIAGNOSIS AND MEDICAL
PREVENTION OF CALCIUM
NEPHROLITHIASIS AND ITS SYSTEMIC
MANIFESTATIONS
(& Educational course on renal stone disease)
Rome (Italy), March 26 – 28, 2015
Organized by
DIVISION OF NEPHROLOGY AND DIALYSIS
COLUMBUS-GEMELLI UNIVERSITY HOSPITAL
UNIVERSITÀ CATTOLICA DEL SACRO CUORE, ROME, ITALY
Promoted by
PROGRAM
Palazzo Brancaccio
Viale del Monte Oppio, 7 - Largo Brancaccio, 82/a
Occurrence of stone disease in the western world has increased
seriously because of the modern lifestyle, dietary habits and overweightproblems. However the relevance of the renal stone disease is not only due
to its inherent urological problems, but also because it is increasingly
regarded as a systemic disorder with a definite risk of end stage kidney, bone
metabolic disease and cardiovascular disease.
The Conference will address the state of the art in metabolic diagnosis
and medical treatment of calcium stone disease and associated systemic
disorders and will be the basis for a consensus statement.
Co-Presidents of the Meeting
Giovanni Gambaro and Emanuele Croppi
–2–
Under the Auspices of
European Renal Association/European Dialysis and
Transplantation Association ERA-EDTA
European Association of Urology EAU-EULIS
Co-Presidents of the Meeting
Emanuele Croppi
Giovanni Gambaro
A.S.L. 10 Florence
Division of Nephrology
Florence, Italy
Columbus-Gemelli University Hospital
Università Cattolica del Sacro Cuore
Rome, Italy
Steering Committee
Fredric L. Coe, Emanuele Croppi, Giovanni Gambaro,
James E. Lingeman, Orson W. Moe, Elaine Worcester
Promoted by
Fondazione Internazionale Menarini
Edificio L – Strada 6
Centro Direzionale Milanofiori
20089 Rozzano (Milan, Italy)
Phone: +39 02 55308110
Fax: +39 02 55305739
E-mail: [email protected]
Http://www.fondazione-menarini.it
Organizing Secretariat - Provider
AVEC S.r.l. - Incentive Paintings - Angela Volpe / Claudia Cislaghi
Via Lavoratori Autobianchi, 1
c/o Polo Tecnologico Brianza - Edificio 9 - Ufficio 14
I-20832 Desio (MB), Italy
Phone: +39 0362 581579 – Fax: +39 0362 544211
E-mail: [email protected] / [email protected]
–3–
Thursday, March 26, 2015 - Afternoon
02.00 p.m. - 03.45 p.m. Reception
03.45 p.m. - 04.00 p.m. Welcome address
G. Gambaro (Rome, I) and E. Croppi (Florence, I)
Session I - The clinical phenotypes of the stone patients
Chair:
O.W. Moe (Dallas, USA)
04.00 p.m. - 04.40 p.m. F.L. Coe (Chicago, USA)
Idiopathic calcium stone patient: how do we
define it?
Calcium Oxalate stones, Brushite stones, Apatite
stones (the phenotype and how to Dx)
04.40 p.m. - 05.00 p.m. D. Fuster (Berne, CH)
Idiopathic calcium stones: separation from Renal
Tubular Acidosis
Is there an incomplete RTA? What is it?
05.00 p.m. - 05.30 p.m. O.W. Moe (Dallas, USA)
Hyperuricosuric calcium stone formers
Is there a rational in using hypouricemic drugs?
Session II - the risk of mbd and ckd in stone formers
Chair:
D.A. Bushinsky (Rochester, USA)
05.30 p.m. - 05.45 p.m. G. Gambaro (Rome, I)
Which stone patient is at high risk of CKD?
05.45 p.m. - 06.00 p.m. D.A. Bushinsky (Rochester, USA)
Which stone patient is at high risk of bone
disease?
What therapies are available? The conventional
interventions for osteoporosis may or may not
work or even be dangerous in stone patients
06.00 p.m.
Welcome cocktail
–4–
Friday, March 27, 2015 – Morning
Session III - The diagnostic work-up in stone patients
Chair:
08.30 a.m. - 9.15 a.m.
D. Milliner (Rochester, USA)
E. Worcester (Chicago, USA)
Detection of systemic causes: what is the best
evaluation?
09.15 a.m. - 09.40 a.m. J. Lieske (Rochester, USA)
Detection of causes in idiopathic
SF 24 hour testing: how important, how many?
09.40 a.m. - 10.20 a.m. M. Marangella (Turin, I)
Can we measure metastability and urinary
inhibitors and promoters for practical use?
Is supersaturation a guide to stone treatment what are the goals. What is the best intermediate
outcome measure when SS is not available (as in
most of Europe). Disorders that promote
supersaturation - can be measured? Importance
for treatment outcome.
Importance for predicting comorbidities?
Importance for future research?
Importance for planing trials?
10.20 a.m. - 10.40 a.m. D. Milliner (Rochester, USA)
Do urine crystals really tell us anything of clinical
value?
10.40 a.m. - 11.10 a.m. Coffee break
Chair:
J.C. Williams (Indianapolis, USA)
11.10 a.m. - 11.40 a.m. J.E. Lingeman (Indianapolis, USA)
Use of surgical observations for diagnosis
Stones not otherwise visible; Papillary appearance
as a guide to Idiopathic stones and secondary
causes of stones
11.40 a.m. - 12.10 a.m. J.C. Williams (Indianapolis, USA)
Crucial nature of stone analysis
Including stone morphology, Quality of
laboratories; role of DE CT
–5–
Friday, March 27, 2015 – Morning
Session IV - Urologist-nephrologist cross-talk
Chair:
G. Capasso (Naples, I)
12.10 a.m. - 12.25 a.m. N. Buchholz (London, UK)
What the urologist asks the nephrologist
Developing a guideline for interaction and joint
follow-up
12.25 a.m. - 12.40 p.m. E. Croppi (Florence, I)
What the nephrologist asks the urologist
Developing a guideline for interaction and joint
follow-up
01.00 p.m. - 02.00 p.m. Lunch
Session V – Treatment: Who should undergo prevention of renal
stones?
Chair:
Ph. Jaeger (Geneve/London, UK)
02.00 p.m. - 02.30 p.m. G.M. Preminger (Durham, USA)
Activity of stone disease; recurrent vs. single stone
formers
Who is recurrent? Does the definition of activity
rely only on stone recurrence and/or growth and/or
need of surgeries. How to gauge formation. Should
we consider also urinary and/or systemic
abnormalities?
–6–
Friday, March 27, 2015 – Afternoon
Session VI – TREATMENT: Prevention of renal stones
Chair:
D. Goldfarb (New York, USA)
02.30 p.m. - 03.00 p.m. P. Strazzullo (Naples, I)
Do any of the diet treatments prevent CaOx
stones?
Low purine; low protein; low sodium; low
oxalate?
03.00 p.m. - 03.30 p.m. R. Siener (Bonn, D)
Is any special beverage likely to matter apart from
being a way to provide water?
03.30 p.m. - 04.00 p.m. K. Sakhaee (Dallas, USA)
When to use citrate?
Is citrate harmful or beneficial for calcium
phosphate stones?
Conversion between stone types, is it a problem?
04.00 p.m. - 04.30 p.m. Coffee break
Chair:
G.C Curhan (Boston, USA)
04.30 p.m. - 05.00 p.m. B. Hess (Zurich, CH)
When to use thiazides or oral phosphate?
05.00 p.m. - 05.30 p.m. I.P. Heilberg (San Paolo, BR)
How do we follow patients?
Metabolic f/u, radiologic f/u
PANEL MEETING (CLOSED SESSION)
Works in small panels for the development of the position statement –
Friday, March 27, 2015 from 05.30 p.m. to 07.30 p.m.
WORKING PANELS (9 panels)
–7–
Saturday, March 28, 2015 – Morning
Chair:
J. Desai (Ahmedabad, India)
08.30 a.m. - 09.30 a.m. J.M. Reis Santos (Lisbon, PT)
Urological treatment of stones: a moving scenario
(educational)
09.30 a.m. - 10.00 a.m. K. Sarica (Instanbul, T)
Guidelines for the urological treatment of stones:
an overview (educational)
10.00 a.m. - 10.30 a.m. Coffee break
Chair:
Z. Kirkali (Bethesda, USA)
10.30 a.m. - 12.30 a.m. Presentations of proposals for the position
paper and plenary discussion
12.30 a.m. - 12.45 a.m. Concluding remarks
12.45 a.m. - 02.00 a.m. Farewell lunch
PANEL MEETING (CLOSED SESSION)
Works in small panels for the development of the position statement
Saturday, March 28, 2015 from 08.30 a.m. to 10.30 a.m.
WORKING PANELS (9 panels)
–8–
GENERAL INFORMATION
Meeting venue
The Congress will take place at Palazzo Brancaccio, Viale del Monte Oppio, 7
– Largo Brancaccio, 82/a - 00184 Rome (Italy).
Secretariat during the Meeting
The desk will be open during the following hours:
Thursday, March 26:
from 01.30 p.m. to 07.00 p.m.
Friday, March 27:
from 08.00 a.m. to 05.30 p.m.
Saturday, March 28:
from 08.00 a.m. to 01.00 p.m.
Official language
The official language of the Meeting will be English. Simultaneous translation
will not be provided.
Registration
Meeting attendance is free of charge for a maximum number of 200 attendances. Please return the Registration form to:
AVEC S.r.l. - Incentive Paintings - Angela Volpe / Claudia Cislaghi
Via Lavoratori Autobianchi, 1 - c/o Polo Tecnologico Brianza - Edificio 9 Ufficio 14 - I-20832 Desio (MB), Italy
Phone: +39 0362 581579 – Fax: +39 0362 544211
E-mail: [email protected] / [email protected]
CME Accreditation
The application for CME accreditation has been submitted with 6 credits for Italian Physicians (Internal Medicine, General Medicine, Endocrinology, Nephrology, Urology, Clinical pathology, Science of Nutrition) and Biologist.
The CME credits will be awarded only after full attendance of all sessions. Completion of the Registration Form, the Learning & Assessment questionnaires are
compulsory.
Technical facilities
Facilities will be available for computer presentations and overhead projections.
A slide centre with PC (Windows and Mac) will be available to check and preview of presentations. Speakers are requested to give a copy of their presentation
on USB memory stick, CD or DVD to the technicians at the slide centre at least
one hour before the session.
–9–
Opening Hours:
Thursday, March 26:
Friday, March 27:
Saturday, March 28:
from 01.30 p.m. to 07.00 p.m.
from 08.00 a.m. to 05.30 p.m.
from 08.00 a.m. to 01.00 p.m.
Lunches and coffee breaks
Lunches and coffee breaks will be served in the Meeting area.
Abstracts book
Participants will receive the Abstract book at the Meeting.
Attendance Certificate
The attendance certificate will be issued at the accreditation desk following full
attendance at the Conference.
– 10 –
INSTRUCTION FOR ABSTRACT PREPARATION
Speakers are requested to prepare a two pages abstract exactly in accordance
with the following instructions.
Guidelines:
• Format. Use A4 format (210 x 297mm) and margins: top – 13,5mm, bottom
– 13,5mm, left – 15mm, right – 15mm. Do not type outside defined area and
do not leave extra margins. The text should be edited in 12-point Times New
Roman. If Times New Roman is not available, a font similar to Times New
Roman should be used.
• Title. Leave three lines of space from the top, then type the paper title in initial capital letters only, without indentation. Make the title bold. Title should
clearly indicate the aim of the presentation.
• Abbreviations should be avoided in the title but they can be used in the text
after defining them first.
• Author's Name. Leave one line of space after the title, and then type the author's full name with initial capitals only. Author's initials are typed after their
names.
• Author’s Address . Leave one line of space, and then type the author's address
in upper and lower case. Please include the full postal address. If authors have
different addresses, please use an asterisk, or similar symbol, to indicate
which authors are at which address. Please start each address on a new line.
• Text. Indent (8.5 mm) the text at the beginning of each new paragraph. Do
not leave a blank line between paragraphs. The text should be justified.
• Abstract should include main references.
• References. The full list of references used for the presentation must also be
provided as a separate file. The Pubmed style should be used. References
should be listed in chronological order starting from the oldest.
• Language. Abstract must be submitted and presented in English.
Submission:
• Abstract must be sent by Friday, December 5, 2014 to the following e-mail
address: [email protected]
Please make sure to send the complete final version of your abstract and list of
references. It will be exactly reproduced as submitted.
– 11 –
LIST OF SPEAKERS, DISCUSSANTS, CHAIRPERSONS AND
CO-PRESIDENTS OF THE MEETING
Bartoletti Riccardo
University of Florence
Department of Urology
Florence, Italy
Buchholz Noor
Sobeh’s Vascular and Medical Center
Department of Urological Surgeon
Dubai, UAE
Bushinsky David
University of Rochester - Medical Center
Department of Nephrology
Rochester, USA
Capasso Giovanbattista
University of Naples
Medicine Division
Naples, Italy
Cicerello Elisa
General Hospital Ca’ Foncello
Department of Urology
Treviso, Italy
Coe Fredric
University of Chicago Medicine
Department of Nephrology
Chicago, USA
Emanuele Croppi
A.S.L. 10 Florence
Florence, Italy
– 12 –
Cupisti Adamasco
University of Pisa
Department of Nephrology
Pisa, Italy
Curhan Gary
Brigham and Women’s Hospital
Renal Division
Boston, USA
Desai Janak
Samved Hospital
Department of Urology
Ahmedabad, India
Fabris Antonia
Maggiore University Hospital
Department of Nephrology
Verona, Italy
Ferraro Pietro Manuel
Catholic University of the Sacred Heart
Columbus University Hospital
Department of Nephrology
Rome, Italy
Fuster Daniel
University of Bern
Department of Nephrology
Bern, Switzerland
Gambaro Giovanni
Catholic University of the Sacred Heart
Columbus University Hospital
Department of Nephrology and Dialysis
Rome, Italy
– 13 –
Goldfarb David
New York Harbor VA Health Care System
Department of Nephrology
New York, USA
Heilberg Ita Pfeferman
Sao Paulo University
Department of Nephrology
Sao Paulo, Brazil
Hess Bernhard
Klinik Im Park Hospital
Department of Internal Medicine & Nephrology
Zurich, Switzerland
Jaeger Philippe
University College of London
Centre of Nephrology
London, UK
Kirkali Ziya
NIDDK, National Institutes of Health
Division of Kidney, Urologic & Hematologic Diseases
Bethesda, USA
Kok Dirk Jan
Erasmus Medical Center
Department of Urology
Rotterdam, Netherlands
Letavernier Emmanuel
Tenon Hospital
Department of Nephrology
Paris, France
Lieske John
Mayo Clinic
Department of Laboratory Medicine and Pathology
Rochester, USA
– 14 –
Lingeman James
Indiana University School of Medicine
Department of Urology
Indianapolis, USA
Marangella Martino
A.S.O Ordine Mauriziano Hospital
Department of Nephrology
Torino, Italy
Mazzaferro Sandro
University La Sapienza
Department of Nephrology
Rome, Italy
Milliner Dawn
Mayo Clinic
Department of Nephrology
Rochester, USA
Moe Orson
University of Texas – Southwestern Medical Center
Department of Internal Medicine
Dallas, USA
Nouvenne Antonio
University of Parma
Department of Internal Medicine
Parma, Italy
Preminger Glenn
Duke University Medical Center
Department of Urology
Durham, USA
Prié Dominique
Necker-Enfants Malades Hospital ,
Department of Physiology
Paris, France
– 15 –
Reis Santos José Manuel
Catholic University of Portugal,
Department of Urology
Lisbon, Portugal
Rendina Domenico
Paris Sud University Hospitals
Medical & Surgical Unit for Obesity - Adolescent Medicine
Paris, France
Sakhaee Khashayar
University of Texas - Southwestern Medical Center
Mineral Metabolism Research
Dallas, USA
Sarica Kemal
University of Ankara
Department of Urology
Ankara, Turkey
Siener Roswitha
University of Bonn
Department of Urology
Bonn, Germany
Soldati Laura
University of Milan
Department of Dietetic Science
Milan, Italy
Strazzullo Pasquale
University of Naples
Department of Internal Medicine
Naples, Italy
Tasca Andrea
San Bortolo Hospital
Department of Urology
Vicenza, Italy
– 16 –
Trinchieri Alberto
Manzoni Hospital
Department of Urology
Lecco, Italy
Vezzoli Giuseppe
San Raffaele University Hospital
Department of Nephrology
Milan, Italy
Vitale Corrado
A.S.O Ordine Mauriziano Hospital
Department of Nephrology and Dialysis
Torino, Italy
Wenqi Wu
Hospital of Guangzhou – Medical College
Department of Urology
Guangzhou, China
Williams James
Indiana University School of Medicine
Department of Anatomy & Cell Biology
Indiana, USA
Worcester Elaine
University of Chicago
Department of Nephrology
Chicago, USA
– 17 –
CONSENSUS CONFERENCE FOR THE METABOLIC
DIAGNOSIS AND MEDICAL PREVENTION OF CALCIUM
NEPHROLITHIASIS AND ITS SYSTEMIC MANIFESTATIONS
(& Educational course on renal stone disease)
Rome (Italy), March 26 – 28, 2015
Promoted by
Physician
Postgraduate
Surname
Name
Title
Professional area
Institute
Address
City
Postcode
Country
Telephone
Mobile
Fax
E-mail
✂
Attendance at the Meeting is free of charge for a maximum number of 200 attendances.
Please return the registration form to:
AVEC S.r.l. - Incentive Paintings - Angela Volpe / Claudia Cislaghi
Via Lavoratori Autobianchi, 1 - c/o Polo Tecnologico Brianza - Edificio 9 - Ufficio 14
I-20832 Desio (MB), Italy - Phone: +39 0362 581579 - Fax: +39 0362 1860074
E-mail: [email protected]
Date
Signature
RE: Informative note pursuant to art. 13 of Legislative Decree 196/2003
Dear Client, this is to inform you that the processing of your personal data will be carried out in our company in full
compliance with Law /2003. As established by this law, the processing will be based on the principles of correctness,
lawfulness and transparency in order to protect your confidentiality and rights.
1) Pursuant to art. 13 we inform you that the data collected will be used for the following purposes:
a. Organization of events, travel incentives, congresses and conventions: performance of bureaucratic procedures,
reservation of tickets for transport, hotels, tourist services; organisational logistics, etc., and/or performance of
accreditation procedures (ECM);
b. Taxation and accounting obligations;
c. Operational and managerial requirements;
d. Possible forwarding of informative and promotional material relating to our sector in printed form or electronically.
2) For data required to fulfil obligations envisaged by law, regulations and Community legislation or provisions issued
by legally empowered authorities and vigilance and control bodies, and to perform our business activities and fulfil our
accounting, taxation and corporate organisational obligations, we are not required to obtain your consent and failure
to provide such data will make it impossible to continue the relationship to the extent that said data are necessary for
performance of the same.
The purchase of products and services marketed by AVEC SRL enables the latter to forward informative, advertising
and promotional material relating to its sector of expertise in compliance with the methods indicated in point 1/d),
pursuant to art. 130 subsection 4 of Legislative Decree 196/2003 and point 6 of the provision ‘Simplification of certain
requirements in the public and private domain concerning data processing for administrative and accounting purposes’ 19 June 2008 Gazzetta Ufficiale (Official Bulletin) no. 152 dated 1 July 2008. Should you decide to object to the
processing operations for commercial purposes, said refusal/objection will not have any consequences of any kind. The
providing of personal data in order to receive advertising and informative material relating to our area of expertise
either in printed form or electronically is entirely optional. Should you decide to object to the processing operations
for commercial purposes, said refusal/objection will not have any consequences of any kind.
3) The personal data are processed by the persons in charge who are assigned to said processing in order to ensure correct
fulfilment of the purposes indicated in point 1) via electronic instruments and printed files, also via use of safety
measures aimed at guaranteeing the confidentiality of the personal data and preventing undue access by unauthorised
subjects. Said data will not be subject to disclosure.
Data may be disclosed to the following subjects in their capacity as autonomous data processing controllers and/or in
charge of external processing:
- accountants for bookkeeping and taxation obligations;
- attorneys for legal assistance for contractual purposes and management of litigation;
- entities/companies which collaborate with our company in the various sectors, for reasons strictly connected to the
purposes set forth in point 1;
- banks and credit institutions.
You may contact the processing controller and persons in charge in order to exercise your rights as set forth in article
7 of Legislative Decree no. 196/2003, that is, the confirmation of the existence or otherwise of the data concerning you,
the erasure, anonymization and blocking of data that has been processed unlawfully, the updating, rectifying or
integrating of data, certification to the effect that the operations have been notified to the entities to whom or which
said data were communicated or disseminated. The right to object to the processing of personal data for the commercial
purposes set forth in point 1 d), where it is carried out via automated contact means, shall also be extended to traditional
means without prejudice to the possibility for the interested party to exercise this right in part, pursuant to art. 7,
subsection 4, letter b), of the Code, that is, by only objecting for example to the sending of promotional communications
with the help of automated means. All requests may be forwarded by email to: [email protected] by phone to:
0362/ 581579 , or by fax to 0362/1860074.
4) The data controller is: AVEC SRL Via Lavoratori, Autobianchi, 1 - Lotto 9/Uff.14 - 20832 – Desio (MB)
5) The person in charge of the processing is: Volpe Angela
The purchase of products and services marketed by AVEC SRL enables the latter to forward informative, advertising and
promotional material relating to its sector of expertise, as set forth in point 1 d), by email or in printed form and also by
means of automated systems, pursuant to point 6 provision ‘Simplification of certain requirements in the public and
private domain concerning data processing for administrative and accounting purposes’ - 19 June 2008 Gazzetta Ufficiale
(Official Bulletin) no. 152 dated 1 July 2008.
❏ If you do not wish to receive such material mark a cross in the box alongside and send this informative note back
to us by email or fax duly signed and stamped. The interested party’s right to object to the processing of personal data
for the commercial purposes set forth in point 1 d), where it is carried out via automated contact means, shall also be
extended to traditional means without prejudice to the possibility for the interested party to exercise this right in part,
pursuant to art. 7, subsection 4, letter b), of the Code, that is, for example by only objecting to the sending of promotional
communications with the help of automated means. Therefore, in the case of any objections, we invite you to specify in
detail*, whether you intend to totally object to the purposes in 1/e, or only to some of the methods (e.g. objection to
sending by fax or email etc.). In case of a general objection then you will not be contacted personally, telephonically or
by email in relation to the promotional activities and initiatives proposed by the company.
*REMARKS:________________________________
Signature for acceptance_______________________________
Menarini Foundation Symposia: 260